News and Updates

PT Kalbe Farma Tbk (Kalbe) through its subsidiaries PT Kalbe Genexine Biologics (KGbio) and PT Finusolprima Farma Internasional (FIMA) launched Efepoetin Alfa drug indicated for anemia therapy in patients with chronic kidney disease. The launch of this drug is a continuation of Kalbe and its subsidiaries after obtaining a distribution license from the Indonesian Food and Drug Administration (Badan POM) in October 2023.

Efesa is pleased to announce that the Ministry of Health (MoH) of Cambodia has officially granted regulatory approval for Efesa on 13 December 2024. This milestone marks significant progress in expanding patient access to innovative treatment options across Southeast Asia.